港股異動丨領航醫藥生物科技一度飆升239%,擬收購Conflux全部股權進軍區塊鏈領域
領航醫藥生物科技(0399.HK)盤初一度飆升漲239.81%,報0.7港元,股價創2017年3月以來新高,目前漲幅收窄至77%,截至目前成交超1500萬港元。消息面上,領航醫藥生物科技宣佈簽署諒解備忘錄,計劃收購一家目標公司的全部股權,前提是該目標公司完成對Conflux區塊鏈相關資產的收購。收購對價將通過現金、公司股份或可換股債券支付,具體金額待定。諒解備忘錄有效期爲12個月,期間賣方不得與第三方就目標公司股權進行談判。此舉旨在幫助領航醫藥拓展區塊鏈技術業務,實現業務多元化並尋找新的盈利增長點。交易尚需簽署正式協議後方可落實。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.